A Phase 3 clinical trial evaluating investigational oral therapy solengepras as a treatment for Parkinson’s disease has dosed its first patient. The ARISE trial (NCT06553027) is evaluating the efficacy of solengepras as a potential add-on therapy to levodopa and other Parkinson’s medications. Patient recruitment is ongoing…

After adding $47 million in new funding, Cerevance is planning to launch a Phase 3 clinical trial to test its oral molecule CVN424, designed to treat people with early-stage Parkinson’s disease without the side effects seen with other therapies, the company announced in a press release. That…

Cerevance has dosed the first participant in a Phase 2 clinical trial evaluating the safety and efficacy of its investigational oral therapy CVN424 for Parkinson’s disease. The ASCEND trial (NCT06006247) will explore the safety and efficacy of CVN424 as a single therapy in people with early-stage…

Cerevance is planning to launch a Phase 2 clinical trial in the second quarter of this year to test its experimental oral medication CVN424 in people newly diagnosed with Parkinson’s disease. The company announced $51 million in new funding, from an expanded round of Series B Financing, for…

Using Cerevance’s oral CVN424 as an add-on therapy for Parkinson’s motor symptoms led to a significant and meaningful dose-dependent reduction in “off” time — periods when symptoms reappear or worsen — data from a Phase 2 study show. The trial also met its safety objectives, according to a…

Cerevance has initiated a Phase 2 clinical trial to evaluate the safety and efficacy of its oral investigational therapy CVN424 for treating Parkinson’s disease motor symptoms. CVN424 is small molecule that can penetrate the brain and modulate the activity of specific nerve cells in the striatum…